PMID- 37678974
OWN - NLM
STAT- MEDLINE
DCOM- 20230915
LR  - 20230927
IS  - 1878-0814 (Electronic)
IS  - 1877-1173 (Linking)
VI  - 199
DP  - 2023
TI  - Universal and hypoimmunogenic pluripotent stem cells for clinical usage.
PG  - 271-296
LID - S1877-1173(23)00059-5 [pii]
LID - 10.1016/bs.pmbts.2023.02.014 [doi]
AB  - It is urgent to prepare and store large numbers of clinical trial grade human 
      pluripotent stem (hPS) cells for off-the-shelf use in stem cell therapies. 
      However, stem cell banks, which store off-the-shelf stem cells, need financial 
      support and large amounts of technicians for daily cell maintenance. Therefore, 
      it is valuable to create "universal" or "hypoimmunogenic" hPS cells with genome 
      editing engineering by knocking in or out immune-related genes. Only a small 
      number of universal or hypoimmunogenic hPS cell lines should be needed to store 
      for off-the-shelf usage and reduce the large amounts of instruments, consumables 
      and technicians. In this article, we consider how to create hypoimmunogenic or 
      universal hPS cells as well as the demerits of the technology. 
      beta2-Microglobulin-knockout hPS cells did not harbor human leukocyte antigen 
      (HLA)-expressing class I cells but led to the activation of natural killer cells. 
      To escape the activities of macrophages and natural killer cells, homozygous hPS 
      cells having a single allele of an HLA class I gene, such as HLA-C, were 
      proposed. Major HLA class Ia molecules were knocked out, and CD47, HLA-G and 
      PD-L1 were knocked in hPS cells utilizing CRISPR/Cas9 genome editing. Finally, 
      some researchers are trying to generate universal hPS cells without genome 
      editing. The cells evaded the activation of not only T cells but also macrophages 
      and natural killer cells. These universal hPS cells have high potential for 
      application in cell therapy.
CI  - Copyright (c) 2023. Published by Elsevier Inc.
FAU - Sung, Tzu-Cheng
AU  - Sung TC
AD  - State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye 
      Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China.
FAU - Maitiruze, Kailibinuer
AU  - Maitiruze K
AD  - State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye 
      Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China.
FAU - Pan, Jiandong
AU  - Pan J
AD  - State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye 
      Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China.
FAU - Gong, Jian
AU  - Gong J
AD  - Department of Laboratory Medicine, The Second Affiliated Hospital and Yuying 
      Children's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China.
FAU - Bai, Yongheng
AU  - Bai Y
AD  - Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of 
      Zhejiang Province, The First Affiliated Hospital, Wenzhou Medical University, The 
      First Affiliated Hospital Area, Wenzhou, Zhejiang, P.R. China.
FAU - Pan, Xiaodong
AU  - Pan X
AD  - Department of Urology, The First Affiliated Hospital, Wenzhou Medical University, 
      The First Affiliated Hospital Area, Wenzhou, Zhejiang, P.R. China.
FAU - Higuchi, Akon
AU  - Higuchi A
AD  - State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye 
      Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, P.R. China; Department 
      of Chemical and Materials Engineering, National Central University, Jhongli, 
      Taoyuan, Taiwan. Electronic address: higuchi@wmu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230316
PL  - Netherlands
TA  - Prog Mol Biol Transl Sci
JT  - Progress in molecular biology and translational science
JID - 101498165
RN  - 0 (HLA Antigens)
SB  - IM
MH  - *Pluripotent Stem Cells/cytology/immunology/metabolism
MH  - HLA Antigens
MH  - Humans
MH  - *Stem Cell Transplantation
MH  - Gene Knockdown Techniques
MH  - Gene Knockout Techniques
MH  - Gene Editing
MH  - Gene Knock-In Techniques
MH  - Animals
MH  - Transplantation Immunology
MH  - Biological Specimen Banks
OTO - NOTNLM
OT  - Cell therapy
OT  - Human leukocyte antigen
OT  - Hypoimmunogenic hPS cells
OT  - Immune privilege
OT  - Off-the-shelf cells
OT  - Universal hPS cells
EDAT- 2023/09/08 00:41
MHDA- 2023/09/11 06:43
CRDT- 2023/09/07 20:57
PHST- 2023/09/11 06:43 [medline]
PHST- 2023/09/08 00:41 [pubmed]
PHST- 2023/09/07 20:57 [entrez]
AID - S1877-1173(23)00059-5 [pii]
AID - 10.1016/bs.pmbts.2023.02.014 [doi]
PST - ppublish
SO  - Prog Mol Biol Transl Sci. 2023;199:271-296. doi: 10.1016/bs.pmbts.2023.02.014. 
      Epub 2023 Mar 16.